

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

|   |  |  |                                   |
|---|--|--|-----------------------------------|
| <b>INFORMATION DISCLOSURE STATEMENT</b>   |  | Docket Number<br><b>12475/49402</b><br>(formerly 12475/31) |                                   |
| Application Number<br><b>10/668,473</b>   | Filing Date<br><b>September 22, 2003</b> | Examiner<br><b>To Be Assigned</b>                          | Art Unit<br><b>To Be Assigned</b> |
| Invention Title<br><b>TRI (ALKYLCARBOXYLATO) GALLIUM (III)<br/>PRODUCTS AND PHARMACEUTICAL<br/>COMPOSITIONS CONTAINING THEM</b> |  | Inventor(s)<br><b>Jack B. JIANG et al.</b>                 |                                   |

Address to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on:

Date: 11/24/04 Reg. No.           
Signature: Bernadette DiSarma

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the following references to the attention of the Examiner. The references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the attached PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
2. Copies of each patent, publication or other information listed on the modified PTO Form No. 1449 are enclosed, unless otherwise indicated.
3. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge deposit account number 11-0600 for such fees. A duplicate copy of this communication is enclosed for charging purposes.


Dated: 11/24/04

By:

John B. Starr, Jr.  
John B. Starr, Jr. (Reg. No. 44,474)

KENYON & KENYON  
One Broadway  
New York, NY 10004  
Telephone: (212) 425-7200  
Facsimile: (212) 425-5288  
Customer No. 26646

© Kenyon & Kenyon 2003



|   |   |                                 |
|---|---|---------------------------------|
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT<br/>PTO-1449</b> | <b>DOCKET NO.</b><br>12475/49402<br>(formerly 12475/31) | <b>SERIAL NO.</b><br>10/668,473 |
|   | <b>APPLICANT</b><br>Jack B. JIANG et al.                |                                 |
|   | <b>FILING DATE</b><br>September 22, 2003                | <b>GROUP</b><br>To Be Assigned  |

**U. S. PATENT DOCUMENTS**

| EXAMINER<br>INITIAL | PATENT<br>NUMBER | PATENT<br>DATE    | NAME                | CLASS | SUBCLASS | FILING<br>DATE* |
|---------------------|------------------|-------------------|---------------------|-------|----------|-----------------|
|                     | 4,529,593*       | July 16, 1985     | Warrell, Jr. et al. |       |          |                 |
|                     | 5,177,068*       | January 5, 1993   | Callingham et al.   |       |          |                 |
|                     | 5,258,376*       | November 2, 1993  | Bernstein           |       |          |                 |
|                     | 5,574,027*       | November 12, 1996 | Bernstein           |       |          |                 |
|                     | 5,747,482*       | May 5, 1998       | Bernstein           |       |          |                 |
|                     | 5,883,088*       | March 16, 1999    | Bernstein           |       |          |                 |
|                     | 5,968,922*       | October 19, 1999  | Bernstein           |       |          |                 |
|                     | 5,981,518*       | November 9, 1999  | Bernstein           |       |          |                 |
|                     | 5,998,397*       | December 7, 1999  | Bernstein           |       |          |                 |
|                     | 6,004,951*       | December 21, 1999 | Bernstein           |       |          |                 |
|                     | 6,048,851*       | April 11, 2000    | Bernstein           |       |          |                 |
|                     | 6,087,354*       | July 11, 2000     | Bernstein           |       |          |                 |
|                     | 6,656,615*       | December 2, 2003  | Dwilinski et al.    |       |          |                 |

\* A copy of the patent is not enclosed since the present application was filed after June 30, 2003.

**FOREIGN PATENT DOCUMENTS**

| EXAMINER<br>INITIAL | DOCUMENT<br>NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION |    |
|---------------------|--------------------|------|---------|-------|----------|-------------|----|
|                     |                    |      |         |       |          | YES         | NO |
|                     |                    |      |         |       |          |             |    |
|                     |                    |      |         |       |          |             |    |
|                     |                    |      |         |       |          |             |    |
|                     |                    |      |         |       |          |             |    |

## OTHER DOCUMENTS

| EXAMINER<br>INITIAL |  | AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.  |
|---------------------|--|---|
|                     |  | Hart et al., "Antitumor Activity and Toxicity of Salts of Inorganic Group IIIa Metals: Aluminum, Gallium, Indium, and Thallium," Proc. Natl. Acad. Sci USA, Vol. 68, No. 7 (July 1971) pp. 1623-1626                              |
|                     |  | D.J. Straus, "Gallium Nitrate in the Treatment of Lymphoma," Seminars in Oncology, Vol. 30, No. 2, Suppl. 5 (April 2003) pp. 25-33  |
|                     |  | E.A. Van Leeuwen-Stok et al., "Cell Cycle Dependency of <sup>67</sup> Gallium Uptake and Cytotoxicity in Human Cell Lines of Hematological Malignancies," Leukemia and Lymphoma, Vol 31(5-6) (November 1998) pp. 533-544          |
|                     |  | R.P. Warrell, Jr. et al., "Salvage Chemotherapy of Advanced Lymphoma with Investigational Drugs: Mitoguazone, Gallium Nitrate, and Etoposide <sup>1,2</sup> ," Cancer Treatment Response, Vol. 71, No. 1 (January 1987) pp. 47-51 |
|                     |  | M.S. Myette et al., "Interaction of gallium nitrate with other inhibitors of ribonucleotide reductase: effects on the proliferation of human leukemic cells," Cancer Letters, Vol. 129, No. 2 (July 17, 1998) pp. 199-204         |
|                     |  | C.R. Chitambar et al., "Evaluation of Continuous-Infusion Gallium Nitrate and Hydroxyurea in Combination for the Treatment of Refractory Non-Hodgkin's Lymphoma," Am. J. Clin. Oncol., Vol. 20, No. 2 (April 1997) pp. 173-178    |
|                     |  | R.P. Warrell et al., "Gallium Nitrate Inhibits Calcium Resorption from Bone and is Effective Treatment for Cancer-related Hypercalcemia," J. Clin. Invest., Vol. 73 (May 1984) pp. 1487-1490                                      |
|                     |  | R.P. Warrell, Jr. et al., "Gallium Nitrate for Preservation of Bone Mass in Multiple Myeloma: Results of a Pilot Randomized Study," Journal of Bone and Mineral Research, Vol. 5 (Suppl. 2) (August 28, 1990) pp. S106            |
|                     |  | R.P. Warrell, Jr. et al., "Low-Dose Gallium Nitrate for Prevention of Osteolysis in Myeloma: Results of a Pilot Randomized Study," Journal of Clinical Oncology, Vol. 11, No. 12 (December 1993) pp. 2443-2450                    |
|                     |  | R.P. Warrell, Jr., "Gallium Nitrate for the Treatment of Bone Metastases," Cancer, Vol. 80, No. 8 (October 15, 1997) pp. 1680-1685  |
|                     |  | C.R. Chitambar, "Gallium Nitrate Revisited," Seminars in Oncology, Vol. 30, No. 2, Suppl. 5 (April 2003) pp. 1-4  |
|                     |  | R.P. Warrell, Jr. et al., "Gallium Nitrate for Advanced Paget Disease of Bone: Effectiveness and Dose-Response Analysis," Annals of Internal Medicine, Vol. 113, No. 11 (December 1990) pp. 847-851                               |
|                     |  | R. Bockman, "The Effects of Gallium Nitrate on Bone Resorption," Seminars in Oncology, Vol. 30, No. 2, Suppl.5 (April 2003) pp. 5-12  |
|                     |  | N. Makkonen et al., "The effect of free gallium and gallium in liposomes on cytokine and nitric oxide secretion from macrophage-like cells in vitro," Inflamm. Res., Vol. 44, No. 12 (December 1995) pp. 523-528                  |
|                     |  | G. Apseloff, "Therapeutic Uses of Gallium Nitrate: Past, Present, and Future," American Journal of Therapeutics, No. 6 (1999) pp. 327-339   |
|                     |  | I.M. Viktorova et al., "Gallium and Indium Acylates," pp. 929-930; translated from Doklady Akademii Nauk SSSR, Vol. 189, No. 3 (November 1969) pp. 541-42   |
|                     |  | H.C. Dudley et al., "Preparation and Properties of Gallium Lactate <sup>1</sup> ," The Journal of the American Chemical Society, Vol. 70 (September-December 1948) p. 3942-3943   |
|                     |  | Per Artursson et al., "Caco-2-Monolayers in Experimental and Theoretical Predictions of Drug Transport," Advanced Drug Delivery Reviews, Vol. 46 (2001) pp. 27-43   |

| EXAMINER<br>INITIAL |  | AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.  |
|---------------------|--|---|
|                     |  | Shiyin Yee, "In Vitro Permeability Across Caco-2-Cells (Colonic) Can Predict in Vivo (Small Intestinal) Absorption in Man - Fact or Myth," <i>Pharmaceutical Research</i> , Vol. 14, No. 6 (1997) pp. 763-766 |
|                     |  | Edward Rudnic et al., "Oral Solid Dosage Forms," Chapter 92, <u>Remington: The Science and Practice of Pharmacy</u> , Vol. II, Alfonso R. Gennaro, Ed., 1995, pp. 1615-1649                                   |

| EXAMINER  | DATE CONSIDERED |
|---|-----------------|
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. |                 |